Kevin Helash - Jul 12, 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC (MBII)

Role: Chief Executive Officer, Director
Signature: /s/ Linda V. Moore, as attorney in fact
Stock symbol: MBII
Transactions as of: Jul 12, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/14/2022, 09:33 PM
Previous filing: Mar 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBII	Common Stock	Disposed to Issuer	$0	-242K	-100%	$0.00^*	0	Jul 12, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer	$0	-417K	-100%	$0.00^*	0	Jul 12, 2022	Common Stock	417K	$0.63	Direct	F2
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer	$0	-2.45M	-100%	$0.00^*	0	Jul 12, 2022	Common Stock	2.45M	$1.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kevin Helash is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Certain unvested restricted stock units became vested and all vested restricted stock units were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement") in exchange for 14,482 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 6,776 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
F2	This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 237,611 shares and replaced with an option to purchase 15,810 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 9,042 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F3	This option, which provided (1) with respect to 225,000 options, for vesting of 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 3, 2020, with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months; (2) with respect to 2,000,000 options, for vesting if/when performance milestone is attained; and (3) with respect to 225,000 options, for vesting over a period of four years as measured from the vesting commencement date of August 4, 2020, on a pro-rata basis equally each month, was assumed by BIOX in the Merger and replaced with an option to purchase 215,600 Ordinary Shares of BIOX for $13.18 per share.